Biology:EuCorVac-19
From HandWiki
Revision as of 15:40, 23 October 2021 by imported>LinXED (add)
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.[1][2][3][4][5]
References
- ↑ "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". United States National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04783311.
- ↑ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". Business Wire. 21 January 2021. https://www.businesswire.com/news/home/20210121005311/en/EuBiologics-Gets-an-IND-Approval-for-Phase-III-Clinical-Trial-of-EuCorVac-19-in-Korea.
- ↑ Moon-hee, Choi (21 January 2021). "EuBiologics Wins Approval on Clinical Trial of COVID-19 Vaccine ‘EuCOVAC-19’". Business Korea. http://www.businesskorea.co.kr/news/articleView.html?idxno=58933.
- ↑ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". EuBiologics. 21 January 2021. http://www.eubiologics.com/eng/sub4_2_view.php?idx=13&page_number=1&mode=&search_gubun=all&search_keyword=.
- ↑ "Firm looks to build vaccine manufacturing plant in PH" (in en). ABS-CBN News. 12 April 2021. https://news.abs-cbn.com/business/04/12/21/firm-looks-to-build-vaccine-manufacturing-plant-in-ph.
 |
